Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 4
1989 1
1992 1
1993 1
1994 4
1995 2
1997 2
1998 1
2000 1
2001 1
2002 2
2003 1
2005 1
2006 2
2007 6
2008 3
2009 2
2010 2
2011 4
2012 5
2013 5
2014 8
2015 5
2016 5
2017 7
2018 9
2019 10
2020 4
2021 4
2022 4
2023 4
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A; GLIMPLES study investigators. Fadini GP, et al. Among authors: anichini r. Diabetes Obes Metab. 2024 Jun;26(6):2390-2400. doi: 10.1111/dom.15554. Epub 2024 Mar 13. Diabetes Obes Metab. 2024. PMID: 38477183
The Effect of Sex and Gender on Diabetic Complications.
Seghieri G, Policardo L, Anichini R, Franconi F, Campesi I, Cherchi S, Tonolo G. Seghieri G, et al. Among authors: anichini r. Curr Diabetes Rev. 2017;13(2):148-160. doi: 10.2174/1573399812666160517115756. Curr Diabetes Rev. 2017. PMID: 27183843 Review.
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2024 Aug;34(8):1846-1853. doi: 10.1016/j.numecd.2024.03.023. Epub 2024 Mar 23. Nutr Metab Cardiovasc Dis. 2024. PMID: 38693036 Free article.
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2023 Nov;33(11):2294-2305. doi: 10.1016/j.numecd.2023.07.025. Epub 2023 Jul 22. Nutr Metab Cardiovasc Dis. 2023. PMID: 37679243 Free article.
[Definition of microalbuminuria].
Giampietro O, Miccoli R, Anichini R, Navalesi R. Giampietro O, et al. Among authors: anichini r. Presse Med. 1988 Jul 2;17(26):1369. Presse Med. 1988. PMID: 2970092 French. No abstract available.
97 results